Premier Biomedical, Inc. announced that they have filed an application with the U.S. Patent Office on a novel approach to the treatment of Cockayne Syndrome. Cockayne Syndrome (CS) is a rare and devastating neurodegenerative disorder characterized by slow growth, premature aging (progeria), shortened lifespan, moderately to severely inhibited neurological development, hearing loss, eye abnormalities/blindness, and sensitivity to sunlight. Cockayne Syndrome is caused by an inherited gene mutation.